Pages that link to "Q46453432"
Jump to navigation
Jump to search
The following pages link to Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms (Q46453432):
Displaying 50 items.
- Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism (Q26864148) (← links)
- Neural control of energy balance: translating circuits to therapies (Q27005992) (← links)
- Androgen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells (Q27013914) (← links)
- Combinations of drugs in the Treatment of Obesity (Q33664063) (← links)
- Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery (Q33772412) (← links)
- Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure (Q33838133) (← links)
- The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease (Q33851630) (← links)
- Amylin activates distributed CNS nuclei to control energy balance (Q33962500) (← links)
- Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates (Q34150227) (← links)
- New pharmacological perspectives for the leptin receptor in the treatment of obesity (Q34330557) (← links)
- Novel strategy for the use of leptin for obesity therapy (Q34454718) (← links)
- Behavioral and pharmacologic therapies for obesity (Q34543656) (← links)
- Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice (Q34718618) (← links)
- Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. (Q35027845) (← links)
- Amylin-induced central IL-6 production enhances ventromedial hypothalamic leptin signaling. (Q35532268) (← links)
- The utility of animal models to evaluate novel anti‐obesity agents (Q35589958) (← links)
- Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake. (Q35749407) (← links)
- Peptides and their potential role in the treatment of diabetes and obesity (Q35760298) (← links)
- Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats (Q36042116) (← links)
- GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities (Q36153247) (← links)
- Effect of proximal versus distal 50% enterectomy on nutritional parameters in rats preconditioned with a high-fat diet or regular chow (Q36323762) (← links)
- Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity (Q36904734) (← links)
- Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C2C12 muscle and AML12 liver cell lines (Q37190598) (← links)
- Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy (Q37368085) (← links)
- Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases (Q37474214) (← links)
- Cardiorenal metabolic syndrome and diabetic cognopathy (Q37514020) (← links)
- Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats (Q37539627) (← links)
- The role of amylin in the control of energy homeostasis (Q37722107) (← links)
- Control of energy homeostasis by amylin (Q37970941) (← links)
- Effects of Amylin on Eating and Adiposity (Q37976361) (← links)
- What is the prognosis for new centrally-acting anti-obesity drugs? (Q37982154) (← links)
- Current and emerging concepts on the role of peripheral signals in the control of food intake and development of obesity (Q37992743) (← links)
- The interaction of amylin with other hormones in the control of eating (Q38031993) (← links)
- Anti-obesity drugs: past, present and future (Q38036925) (← links)
- Understanding synergy (Q38065010) (← links)
- Leptin therapy in type 2 diabetes (Q38065316) (← links)
- Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. (Q38088108) (← links)
- A long journey to effective obesity treatments: is there light at the end of the tunnel? (Q38121752) (← links)
- The central question of type 2 diabetes (Q38162978) (← links)
- New molecular targets in the pathophysiology of obesity and available treatment options under investigation (Q38397535) (← links)
- Amylin-mediated control of glycemia, energy balance, and cognition (Q38753342) (← links)
- The New Biology and Pharmacology of Glucagon. (Q38919742) (← links)
- Physiologic and Neural Controls of Eating (Q39006267) (← links)
- 10 lessons learned by a misguided physician (Q39052174) (← links)
- IL-6 ameliorates defective leptin sensitivity in DIO ventromedial hypothalamic nucleus neurons. (Q39480710) (← links)
- Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations (Q41944545) (← links)
- Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner (Q42134405) (← links)
- Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats. (Q42326757) (← links)
- Recent progress and novel perspectives on obesity pharmacotherapy (Q42881681) (← links)
- Early postnatal amylin treatment enhances hypothalamic leptin signaling and neural development in the selectively bred diet-induced obese rat. (Q45848313) (← links)